, Volume 173, Issue 3–4, pp 425–433 | Cite as

Empathy and aggression: two faces of ecstasy? A study of interpretative cognitive bias and mood change in ecstasy users

  • H. Valerie Curran
  • Huw Rees
  • Thomas Hoare
  • Rosa Hoshi
  • Alyson Bond
Original Investigation



As central 5-hydroxytryptamine (5-HT) is attenuated for a period following a single dose of MDMA (“ecstasy”) and low 5-HT is associated with aggression, then MDMA users may be more aggressive in the days following an acute dose of the drug.


This study therefore aimed to determine if acute use of MDMA is associated with aggression 4 and 7 days later.


Twenty-nine MDMA users and 32 controls were compared on self-rated aggression and depression on the night of drug use (day 0), 4 and 7 days later. On day 4, participants performed an interpretative bias task in which they processed ambiguous sentences that could be interpreted in either an aggressive or neutral way (e.g. “The painter drew the knife”).


MDMA users had faster response times in completing ambiguous aggressive sentences than neutral sentences; controls showed the opposite pattern of performance. In a subsequent recognition task, MDMA users were more confident in judging, and responded faster to, aggressive than neutral sentences; controls again showed the opposite pattern of effects. The level of aggressive interpretative bias positively correlated with extent of MDMA use. Midweek, MDMA users had higher self-rated aggression and depression scores than controls; on day 7, scores of both groups were similar.


MDMA users display a cognitive bias towards interpreting ambiguous information in an aggressive way a few days after taking the drug. Self-rated mid-week low mood and mid-week aggression do not persist 7 days after use of the drug. This pattern of results is consistent both with the acute and residual effects of MDMA on central 5-HT and with the notion that 5-HT plays a role in modulating human aggression.


MDMA Ecstasy Aggression Depression Cognitive bias Interpretative bias 



None of the authors have any interest, financial or otherwise, that might potentially bias their work. We thank Dr. Suzanne Verheyden for comments on an earlier draft of this article.


  1. Beck AT (1978) The Beck Depression Inventory (BDI). The Psychological Corporation, Harcourt Brace JovanovitzGoogle Scholar
  2. Bond AJ, Lader MH (1974) The use of analogue scales in rating subjective feelings. Br J Med Psychol 47:211–218Google Scholar
  3. Bond AJ, Lader MH (1986) A method to elicit aggressive feelings and behaviour via provocation. Biol Psychol 22:69–79PubMedGoogle Scholar
  4. Bond AJ, Wingrove J, Critchlow DG (2001) Tryptophan depletion increases aggression in women during the premenstrual phase. Psychopharmacology 156:477–480CrossRefPubMedGoogle Scholar
  5. Brown GL, Goodwin FK, Ballenger JC, Goyer PF, Major LF (1979) Aggression in humans correlates with cerebrospinal fluid amine metabolites. Psychiatry Res 1:131–139PubMedGoogle Scholar
  6. Buss AH, Perry M (1992) The aggression questionnaire. J Person Soc Psychol 63:452–459Google Scholar
  7. Cami J, Farre M, Mas M, Roset PN, Poudevida S, Mas A, San L, de la Torre R. (2000) Human pharmacology of 3,4-methylenedioxymethamphetamine (“ecstasy”): psychomotor performance and subjective effects. J Clin Psychopharmacol 20:455–466CrossRefPubMedGoogle Scholar
  8. Cleare AJ, Bond AJ (1995) The effect of tryptophan depletion and enhancement on subjective and behavioural aggression in normal male subjects. Psychopharmacology 118:72–81Google Scholar
  9. Cleare AJ, Bond AJ (1997) Does central serotonergic function correlate inversely with aggression? A study using d-fenfluramine in healthy subjects. Psychiatry Res 69:89–95PubMedGoogle Scholar
  10. Coccaro EF, Siever LJ, Klar HM, Maurer G, Cochrane K, Cooper TB, Mohs RC, Davis KL (1989) Serotonergic studies in patients with affective and personality disorders. Correlates with suicidal and impulsive aggressive behavior. Arch Gen Psychiatry 46:587–599PubMedGoogle Scholar
  11. Copello AG, Tata PR (1990) Violent behaviour and interpretative bias: an experimental study of the resolution of ambiguity in violent offenders. Br J Clin Psychol 29:417–428PubMedGoogle Scholar
  12. Cowen PJ (1991). Serotonin receptor subtypes: implications for psychopharmacology. Br J Psychiatry Suppl 12:7–14PubMedGoogle Scholar
  13. Curran HV (2000) Is MDMA (ecstasy) neurotoxic in humans? An overview of evidence and of methodological problems in research. Neuropsychobiology 42:34–41PubMedGoogle Scholar
  14. Curran HV, Travill RA (1997) Mood and cognitive effects of 3,4 methylenedioxymethamphetamine (MDMA, “ecstasy”): weekend “high” followed by midweek “low”. Addiction 92:821–831CrossRefPubMedGoogle Scholar
  15. Curran HV, Verheyden SL (2003) Altered response to tryptophan supplementation after long-term abstention from MDMA (“ecstasy”) is highly correlated with human memory function. Psychopharmacology 169:91–103CrossRefPubMedGoogle Scholar
  16. Gerra G, Zaimovic A, Giucastro G, Maestri D, Monica C, Sartori R, Caccavari R, Delssignore R (1998) Serotonergic function after 3,4 methylenedioxymethamphetamine (“ecstasy”) in humans. Int Clin Pharmacol 13:1–9Google Scholar
  17. Gerra G, Zaimovic A, Ampollinin R, Giusti F, Delsignore R, Raggi MA, Laviola G, Macchia T, Brambilla F (2001) Experimentally induced aggressive behaviour in subjects with 3,4 methylenedioxymethamphetamine (“ecstasy”) use history. Psychobiological correlates. J Subst Misuse 13:471–491CrossRefGoogle Scholar
  18. Goodwin GM, DeSouza RJ, Green AR (1985) Presynaptic serotonin receptor-mediated response in mice attenuated by antidepressant drugs and electroconvulsive shock. Nature 317:531–533PubMedGoogle Scholar
  19. Green AR, Cross AJ, Goodwin GM (1995) Review of the pharmacology and clinical pharmacology of 3,4 methylenedioxymethamphetamine (MDMA or ecstasy). Psychopharmacology 119:247–260PubMedGoogle Scholar
  20. Liechti ME, Gamma A, Vollenweider FX (2001) Gender differences in the subjective effects of MDMA. Psychopharmacology 154:161–168PubMedGoogle Scholar
  21. Linnoila M, Virkkunen M (1992) Biologic correlates of suicidal risk and aggressive behavioural traits. J Clin Psychopharmacol 12:19S–20SPubMedGoogle Scholar
  22. Linnoila M, Virkkunen M, George T, Higley D (1993) Impulse control disorders. Int Clin Psychopharmacol 8:53–56Google Scholar
  23. McCann UD, Ridenour A, Shaham Y, Ricaurte GA (1994) Serotonin neurotoxicity after (±)3,4-methylenedioxymethamphetamine (MDMA; “ecstasy”): a controlled study in humans Neuropsychopharmacology 10:129–138Google Scholar
  24. McKenna DJ, Peroutka SJ (1990) Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) J Neurochem 541:14–22Google Scholar
  25. Morgan MJ (1998) Recreational use of ecstasy (MDMA) is associated with elevated impulsivity. Neuropsychopharmacology 19:252–264CrossRefPubMedGoogle Scholar
  26. Novaco RW (1978) Anger and coping with stress: Cognitive behavioural intervention. In: Foreyt JP, Rathjen P (eds) Cognitive behavioural therapy: research and application. Plenum Press, New York/LondonGoogle Scholar
  27. Parrott AC, Lasky J (1998) Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology 139:261–268CrossRefPubMedGoogle Scholar
  28. Rattray M (1991) Ecstasy: towards an understanding of the biochemical basis of the actions of MDMA. Essays Biochem 26:77–87PubMedGoogle Scholar
  29. Schmidt C J, Wu L, Lovenberg W (1986) Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue. Eur J Pharmacol 124:175–178PubMedGoogle Scholar
  30. Smith KA, Fairburn CG, Cowen PJ (1997) Relapse of depression after rapid depletion of tryptophan. Lancet 349:915–919PubMedGoogle Scholar
  31. Solowij N, Hall W, Lee N (1992) Recreational MDMA use in Sydney: a profile of “ecstasy” users and their experiences with the drug. Br J Addict 87:1161–1172PubMedGoogle Scholar
  32. Verheyden SL, Hadfield J, Calin T, Curran HV (2002) Sub-acute effects of MDMA (3,4 methylenedioxymethamphetamine, “ecstasy”) on mood: evidence of gender differences. Psychopharmacology 161:23–31CrossRefPubMedGoogle Scholar
  33. Vollenweider FX, Gamma A, Liechti M, Huber T (1998). Psychological and cardiovascular effects and short-term sequelae of MDMA (“ecstasy”) in MDMA-naive healthy volunteers. Neuropsychopharmacology 19:241–251CrossRefPubMedGoogle Scholar
  34. Young SN, Leyton M (2002) The role of serotonin in human mood and social interaction: insight from altered tryptophan levels. Pharmacol Biochem Behav 71:857–865Google Scholar
  35. Zigmond AS, Snaith RP (1983) The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 67:361–370PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • H. Valerie Curran
    • 1
  • Huw Rees
    • 1
  • Thomas Hoare
    • 1
  • Rosa Hoshi
    • 1
  • Alyson Bond
    • 2
  1. 1.Clinical Psychopharmacology UnitUniversity College LondonLondonUK
  2. 2.National Addiction CentreInstitute of PsychiatryLondonUK

Personalised recommendations